Literature DB >> 12431133

Ulcerative colitis in children: medical management.

David A Gremse1, Karen D Crissinger.   

Abstract

Ulcerative colitis is a chronic relapsing inflammatory disorder of the colonic mucosa of unknown etiology. The inflammatory process involves the mucosa and submucosa in a continuous segment of bowel with rectal involvement in almost all cases. Since its etiology is unknown, therapy is directed at modulating the inflammatory response in order to control symptoms and to prevent relapses. 5-aminosalicylates and corticosteroids have been the most widely used therapeutic agents for treatment of ulcerative colitis. Recently, experience has been gained with the use of other immunomodulators, such as mercaptopurine, azathioprine, methotrexate, cyclosporine, and tacrolimus, in pediatric patients. Colectomy is indicated in patients with severe colitis who do not respond to intensive medical therapy. The care of children with ulcerative colitis not only involves control of symptoms from gastrointestinal and extraintestinal manifestations, but also optimizing growth and development. The complications of chronic inflammation and long-term medical therapy must be weighed against the risks and benefits of surgery for children and adolescents with this condition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12431133     DOI: 10.2165/00128072-200204120-00005

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  56 in total

1.  Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis.

Authors:  H E LOCKHART-MUMMERY; B C MORSON
Journal:  Gut       Date:  1960-06       Impact factor: 23.059

2.  Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease: prevalence and diagnostic value.

Authors:  J P Olives; A Breton; J P Hugot; F Oksman; C Johannet; J Ghisolfi; J Navarro; J P Cézard
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-08       Impact factor: 2.839

Review 3.  The treatment of inflammatory bowel disease in children.

Authors:  R Wyllie; S Sarigol
Journal:  Clin Pediatr (Phila)       Date:  1998-07       Impact factor: 1.168

Review 4.  Colonoscopic surveillance for cancer in ulcerative colitis: a critical review.

Authors:  A M Griffiths; P M Sherman
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-02       Impact factor: 2.839

5.  Landmark article Oct 15, 1932. Regional ileitis. A pathological and clinical entity. By Burril B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer.

Authors:  B B Crohn; L Ginzburg; G D Oppenheimer
Journal:  JAMA       Date:  1984-01-06       Impact factor: 56.272

6.  Inflammatory bowel disease.

Authors:  J M Moll
Journal:  Clin Rheum Dis       Date:  1985-04

Review 7.  The modern medical management of acute, severe ulcerative colitis.

Authors:  J F Marion; D H Present
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-09       Impact factor: 2.566

8.  Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.

Authors:  W Kruis; J W Brandes; S Schreiber; D Theuer; B Krakamp; E Schütz; P Otto; H Lorenz-Mayer; K Ewe; G Judmaier
Journal:  Aliment Pharmacol Ther       Date:  1998-08       Impact factor: 8.171

9.  Outcome after ileoanal anastomosis in pediatric patients with ulcerative colitis.

Authors:  C Durno; P Sherman; K Harris; C Smith; A Dupuis; B Shandling; D Wesson; R Filler; R Superina; A Griffiths
Journal:  J Pediatr Gastroenterol Nutr       Date:  1998-11       Impact factor: 2.839

10.  Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial.

Authors:  G D Ferry; B S Kirschner; R J Grand; R M Issenman; A M Griffiths; J A Vanderhoof; S C Fiedorek; H S Winter; E G Hassall; J B Watkins
Journal:  J Pediatr Gastroenterol Nutr       Date:  1993-07       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.